Clinical Trials Logo

Chronic Hepatitis B clinical trials

View clinical trials related to Chronic Hepatitis B.

Filter by:

NCT ID: NCT03847246 Completed - Chronic Hepatitis b Clinical Trials

Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers

Start date: December 4, 2018
Phase: N/A
Study type: Interventional

A single-center, open-Label, randomized, single-dose, two-period, two-sequence, crossover study to assess the bioequivalence of test formulation entecavir tablets 1.0 mg with reference formulation entecavir tablets (Baraclude®) 1.0 mg in healthy adult subjects under fasting conditions.

NCT ID: NCT03734783 Completed - Chronic Hepatitis b Clinical Trials

IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB

Start date: July 1, 2017
Phase:
Study type: Observational [Patient Registry]

The investigators observed the level of IL-35 secreting B regulatory (IL-35+Bregs) cells in peripheral blood cells in patients with chronic hepatitis B, and analysed the relationship between the IL-35+Bregs level and disease stage, and Th1 and Th2 cells level.

NCT ID: NCT03714152 Completed - Chronic Hepatitis B Clinical Trials

A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B

Start date: November 13, 2018
Phase: Phase 1
Study type: Interventional

This three-part, Phase 1 protocol will be the first clinical study of ABI-H2158. Parts 1 and 2 will be a Phase 1a, dose-ranging assessment of ABI-H2158 in healthy adult volunteers. If the dose-related safety, tolerability, and pharmacokinetics (PK) of ABI-H2158 in healthy volunteers are deemed satisfactory, then the study will advance to Part 3, a Phase 1b, dose-ranging assessment of ABI-H2158 in non-cirrhotic, CHB patients.

NCT ID: NCT03672188 Completed - Chronic Hepatitis B Clinical Trials

Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B

Start date: November 14, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 study in which healthy adult subjects and subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 or placebo and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity (only in subjects with chronic HBV). In the single ascending dose (SAD) part, Part A, healthy adult subjects will receive one dose of VIR-2218 or placebo, administered subcutaneously (SC). In the multiple ascending dose (MAD) parts, Part B & Part C, subjects with chronic HBV infection will receive two doses of VIR-2218 or placebo every 4 weeks administered SC.

NCT ID: NCT03662568 Completed - Chronic Hepatitis B Clinical Trials

A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects

Start date: June 26, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of Morphothiadine Mesilate/Ritonavir combined with Entecavir or Tenofovir Disoproxil Fumarate in healthy subjects

NCT ID: NCT03638076 Completed - Chronic Hepatitis B Clinical Trials

The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules

Start date: July 26, 2017
Phase: Phase 2
Study type: Interventional

The Safety, Antiviral Activity, and pharmacokinetics of Morphothiadine Mesilate Capsules/Ritonavir Tablets in Patients with Chronic Hepatitis B

NCT ID: NCT03615066 Completed - Chronic Hepatitis B Clinical Trials

Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment

Start date: August 28, 2018
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are to evaluate the safety and tolerability of multiple oral doses of selgantolimod and to evaluate the antiviral activity of selgantolimod in adult participants with chronic hepatitis B (CHB) who are viremic and not currently being treated.

NCT ID: NCT03585322 Completed - Chronic Hepatitis B Clinical Trials

APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

Start date: July 4, 2018
Phase: Phase 1
Study type: Interventional

This study is a Multiple Ascending Dose study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of APG-1387 in Chronic Hepatitis B Patients.

NCT ID: NCT03577171 Completed - Chronic Hepatitis B Clinical Trials

A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)

Start date: June 19, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if ABI-H0731 given in combination with a standard of care (SOC) entecavir (ETV) is safe and effective in participants with chronic hepatitis B infection (cHBV)

NCT ID: NCT03576066 Completed - Chronic Hepatitis B Clinical Trials

A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection

Start date: June 11, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if ABI-H0731 given in combination with a standard of care (SOC) hepatitis B virus (HBV) nucleos(t)ide reverse transcriptase inhibitor (NUC) medication is safe and effective in participants with chronic hepatitis B virus infection (cHBV).